-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rosnilimab in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rosnilimab in Rheumatoid Arthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rosnilimab in Rheumatoid Arthritis Drug Details: Rosnilimab (ANB-030) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rosnilimab in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rosnilimab in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rosnilimab in Ulcerative Colitis Drug Details: Rosnilimab (ANB-030) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rosnilimab in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rosnilimab in Vitiligo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rosnilimab in Vitiligo Drug Details: Rosnilimab (ANB-030) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rosnilimab in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rosnilimab in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rosnilimab in Graft Versus Host Disease (GVHD) Drug...
-
Product Insights
NewNet Present Value Model: AnaptysBio Inc’s ANB-032
Empower your strategies with our Net Present Value Model: AnaptysBio Inc's ANB-032 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – AnaptysBio Inc
AnaptysBio Inc (AnaptysBio) is a clinical-stage biotechnology company that focuses on the development of antibody candidates for the treatment of atopic dermatitis, ovarian cancer, lung cancer, asthma, psoriasis, inflammation, and other autoimmune indications. The company develops its product candidates through its proprietary antibody discovery technology platform that is based on somatic hypermutation (SHM). The company has various product candidates under development for the treatment of moderate-to-severe adult atopic dermatitis, asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis, and human autoimmune...
-
Product Insights
NewNet Present Value Model: AnaptysBio Inc’s Rosnilimab
Empower your strategies with our Net Present Value Model: AnaptysBio Inc's Rosnilimab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewVitiligo – Drugs In Development, 2024
Empower your strategies with our Vitiligo – Drugs In Development, 2024 report and make more profitable business decisions. Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair, and eyes. Symptoms include premature whitening or graying of the hair on teh scalp, eyelashes, eyebrows, or beard; loss of color in the tissues that line the inside of mouth; and loss of or change in color of the inner layer of eye. Treatment includes...
-
Product Insights
NewGeneralized Pustular Psoriasis (GPP) – Drugs In Development, 2024
Empower your strategies with our Generalized Pustular Psoriasis (GPP) – Drugs In Development, 2024 report and make more profitable business decisions. Pustular psoriasis is a rare and extreme form of psoriasis characterized by the appearance of sterile pustules which can take many patterns. All the main pathological features of the disease are accentuated. Generalized pustular psoriasis is clinically heterogeneous in its age at onset, precipitants, severity, and natural history. Generalized pustular psoriasis is often associated with metabolic syndrome and polyarthritis The...
-
Product Insights
NewGraft Versus Host Disease (GVHD) – Drugs In Development, 2024
Empower your strategies with our Graft Versus Host Disease (GVHD) – Drugs In Development, 2024 report and make more profitable business decisions. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps; nausea, vomiting, and diarrhea; dry or irritated eyes; jaundice; shortness of breath; vaginal dryness; and weight loss. Treatment includes immunosuppressants. The Graft Versus Host...